Budesonide is a corticosteroid with lower systemic absorption than older steroids like prednisone, but using it for months or years can still produce side effects. The specific risks depend heavily on how you take it (inhaled, oral, or nasal) and the dose, but the most commonly reported long-term concerns involve bone health, adrenal function, skin changes, eye pressure, growth in children, and respiratory infections.
Bone Density and Fracture Risk
Bone loss is one of the first concerns people have with any steroid, but budesonide’s impact on bones is more nuanced than many expect. In a study of inflammatory bowel disease patients who took oral budesonide for an average of nearly four years, spine bone density actually improved during treatment, and hip bone density stayed stable. No fragility fractures occurred during the follow-up period.
A broader meta-analysis found that long-term budesonide maintenance was associated with osteoporosis in about 24.7% of patients and osteopenia (the milder stage of bone thinning) in 26.4%. Those numbers are not dramatically different from comparison groups not taking steroids, where the rates were 29.1% and 23.0%, respectively. That said, a large Danish cohort study did find a roughly doubled risk of spinal fractures (odds ratio of 1.98) in patients who had used budesonide, with a smaller, non-significant increase in hip fracture risk. So while budesonide is gentler on bones than traditional steroids, spinal fracture risk may still be elevated with prolonged use.
Adrenal Suppression
Your adrenal glands produce cortisol naturally, and when you take a corticosteroid for a long time, the glands can “dial down” their own output. This is called adrenal suppression, and it matters most if you suddenly stop the medication or face physical stress like surgery or severe illness, when your body needs a cortisol surge it can no longer produce on its own.
For inhaled budesonide at low to moderate doses, the risk of clinically meaningful adrenal suppression is minimal. At higher inhaled doses (generally above 800 micrograms per day) used long-term, the risk increases substantially, and some patients in that range may need supplemental steroids during surgeries, infections, or other physical stressors. Oral budesonide carries a higher risk than inhaled forms because more of the drug reaches the bloodstream. This is why doctors taper budesonide gradually rather than stopping it abruptly.
Skin Bruising and Thinning
Easy bruising is one of the more common and visible long-term effects. In studies of patients taking high-dose inhaled steroids (800 to 2,000 micrograms daily), about 47 to 71% reported skin bruising, compared to 12 to 32% of people not using inhaled steroids. On direct skin examination, roughly 48% of high-dose users showed visible bruising. Skin thinning and acne have also been linked to long-term inhaled steroid use.
These skin effects were similar between budesonide and another common inhaled steroid (beclomethasone), suggesting this is a class-wide issue rather than something unique to budesonide. At lower inhaled doses, these problems are less frequent, though they can still occur over years of use.
Eye Problems: Cataracts and Glaucoma
Steroid use in general is associated with cataracts and increased eye pressure (a risk factor for glaucoma), but budesonide’s track record here is relatively reassuring. A study in children using inhaled budesonide found that doses up to 800 micrograms daily for short periods, and long-term use at 200 to 400 micrograms daily, did not cause lens opacities or clinically important increases in eye pressure. Three children showed slight pressure increases at higher doses, but overall, budesonide did not raise eye pressure on average.
That said, these findings come primarily from pediatric data at moderate doses. Adults using higher doses for many years may face different odds, and periodic eye exams remain a reasonable precaution for anyone on long-term steroid therapy.
Growth Effects in Children
Children who use inhaled budesonide for asthma can end up slightly shorter as adults. A well-known trial published in The New England Journal of Medicine followed children from early treatment through to their final adult height and found that the budesonide group was, on average, 1.2 centimeters shorter than the placebo group. That difference appeared within the first two years of treatment (1.3 cm reduction at the two-year mark) and did not worsen further over time, suggesting the growth effect is an early, one-time impact rather than an ongoing loss.
Higher daily doses produced a larger effect: each additional microgram per kilogram of body weight was linked to an extra 0.1 cm of lost height. For most children, the total reduction is small enough that the benefits of asthma control outweigh the height trade-off, but it is a real and permanent effect worth discussing with a pediatrician when starting long-term therapy.
Respiratory Infections and Pneumonia
Inhaled corticosteroids suppress local immune defenses in the airways, which can increase the risk of respiratory infections. In a large UK population-based study of patients with COPD, recent inhaled corticosteroid use (within the previous 180 days) raised the odds of pneumonia by about 26%. This risk appears to be a class effect of inhaled steroids generally. Some evidence suggests budesonide may carry a lower pneumonia risk than another widely used inhaled steroid (fluticasone), though both increase risk compared to not using inhaled steroids at all.
Oral thrush (a yeast infection in the mouth) is another common issue with inhaled budesonide. Rinsing your mouth and spitting after each dose significantly reduces this risk, and using a spacer device with a metered-dose inhaler helps keep the drug out of the back of your throat.
How the Form of Budesonide Changes the Risk
The side effect profile shifts considerably depending on how you take budesonide. Inhaled budesonide (for asthma or COPD) delivers the drug directly to the lungs, with relatively little entering the bloodstream. Most of the effects described above, like skin bruising and mild adrenal suppression, become concerns primarily at higher inhaled doses used for years.
Oral budesonide (used for Crohn’s disease, ulcerative colitis, or microscopic colitis) reaches the bloodstream in larger amounts despite being designed for partial first-pass metabolism in the liver. This means oral forms carry a higher risk of systemic effects like adrenal suppression, blood sugar changes, and bone thinning, though still less than equivalent doses of prednisone. Nasal budesonide sprays, used for allergies and sinus conditions, have the lowest systemic absorption and the mildest long-term risk profile of all three forms.
Regardless of the form, the pattern is consistent: risk scales with dose and duration. The lowest effective dose for the shortest necessary time remains the core strategy for minimizing long-term effects.